Hepatic ischemia/reperfusion injury (IRI), an inevitable antigen-independent inflammation response in cadaveric liver transplantation, correlates with poor early graft function, rejection episodes, and contributes to donor organ shortage. Sirtuin 1 (SIRT1) is a histone deacetylase that may regulate inflammatory cell activity and manage liver function in IRI, though its functional role and clinical relevance remains to be elucidated. We investigated the efficacy of SIRT1 activation in a murine liver IRI model and verified the concept of putative SIRT1-mediated hepatoprotection in clinical liver transplantation. In the experimental arm, mice were subjected to 90 minutes of liver partial warm ischemia followed by 6 hours of reperfusion with or without adjunctive SIRT1 activation in vivo (resveratrol [Res]). In parallel, bone marrow-derived macrophage (BMDM) or spleen lymphocyte cultures were treated with Res. In the clinical arm, liver biopsies from 21 adult primary liver transplant patients (2 hours after reperfusion) were divided into "low" (n 5 11) versus "high" (n 5 10) SIRT1 expression groups, assessed by Western blots. Treatment with Res attenuated murine liver IRI while up-regulating SIRT1, suppressing leukocyte infiltration, and decreasing proinflammatory cytokine programs. SIRT1 silencing (small interfering RNA) in BMDM cultures enhanced inflammatory cytokine programs, whereas addition of Res decreased proinflammatory response in a SIRT1-dependent manner. In addition, Res decreased interferon c production in liverinfiltrating and spleen lymphocyte cultures. Human liver transplants with high SIRT1 levels showed improved hepatocellular function and superior survival (P 5 0.04), accompanied by lower proinflammatory cytokine profile. In conclusion, our translational study is the first to identify SIRT1 as a regulator of hepatocellular function in human liver transplant recipients under ischemia/reperfusion stress. By targeting innate and adaptive immune activation, manipulation of SIRT1 signaling should be considered as a novel means to combat inflammation in liver transplantation.
triggered by toll-like receptor 4 signaling. (2) Because T-lymphocytes also mediate ischemia/reperfusion (IR)-liver inflammation, (3) regulating macrophage and T-lymphocyte activation interface is a critical step in developing novel therapeutic means against IRI in transplant recipients. (3) Sirtuin 1 (SIRT1) is a member of the class III histone/protein deacetylase involved in cellular senescence, inflammation, and stress resistance. (4) Previous studies have shown that SIRT1 induction not only suppressed macrophage activation (5) but also inhibited CD41 T cell T helper 1 (T h 1) cytokine production, (6) suggesting SIRT1 activation as a promising strategy to protect the liver against IR stress. Although carbon monoxide inhalation (7) or calorie starvation (8) protect mice against liver IR insult while increasing SIRT1 levels, the mechanistic insights and clinical relevance of these findings remains debatable. Recently, pharmacological SIRT1 activation (2-ME2, (9) SIRT1720 (10, 11) ) or adenoviral SIRT1 overexpression (11) was shown to mitigate liver IRI. No studies on human hepatic SIRT1 expression or liver transplant clinical outcomes were reported to date.
Resveratrol (Res; 3,4,5-trihydroxystilbene) is a natural polyphenolic phytoalexin present in plant species, including grape and peanut. (12) While screening for small molecule SIRT1 activators, Howitz et al. identified 21 different SIRT1-activating molecules, with Res being the most potent compound among them. (13) Previous preclinical studies have shown Res-mediated beneficial biological effects, including life-span extension, insulin-resistance, cancer-prevention, and anti-inflammatory functions. (14, 15) On the basis of a plethora of clinical trials, it is becoming evident that Res may exert health benefits in humans, including cardiovascular protection. (16) Because Res mediates the majority of key target molecules by SIRT1-depending manner, including adenosine monophosphate-activated protein kinase and peroxisome proliferator-activated receptor-gamma coactivator 1a (PGC1a), (17) SIRT1 activation is considered a key feature of Res treatment benefits, (18) while some SIRT1-independent mechanisms are also reported. (17) Despite previous observational studies on protective effects of Res treatment in rat liver IRI models, (19, 20) the function of SIRT1 in Resmediated liver protection remains to be elucidated.
Our present in vivo and in vitro results from welldefined mouse models confirm protective effects of Res against liver IRI, accompanied by SIRT1 upregulation and macrophage/T-lymphocyte inhibition. Concomitant evaluation of postreperfusion human liver transplant biopsies (bxs) demonstrated, for the first time, that increased SIRT1 expression associated with a depressed proinflammatory cytokine program, improved hepatocellular function and superior posttransplant survival. Our findings validate a novel concept of SIRT1 activation in clinical liver transplantation.
Materials and Methods

CLINICAL LIVER TRANSPLANT STUDY/SAMPLE COLLECTION
Twenty-one adult primary orthotopic liver transplantation (OLT) recipients were recruited under institutional review board protocol (13-000143) between inducible nitric oxide synthase; IP, intraperitoneally; IR, ischemia/ reperfusion; IRI, ischemia/reperfusion injury; LPS, lipopolysaccharide; Ly6-G, lymphocyte antigen 6 complex locus G; MCP1, monocyte chemoattractant protein 1; mRNA, messenger RNA; Nec-1s, 7-Cl-ONec-1 necrosis inhibitor; NF-jB, nuclear factor kappa B; OLT, orthotopic liver transplantation; PGC-1a, peroxisome proliferatoractivated receptor-gamma coactivator 1a; p-IjBa, phospho I kappa B alpha; POD, postoperative day; p-Stat1, phospho signal transducer and activator of transcription 1; RAW cell, RAW 264.7; Res, resveratrol; ROC, receiver operating characteristics; RT-PCR, real-time polymerase chain reaction; SD, standard deviation; SEM, standard error of the mean; siRNA, small interfering RNA; SIRT1, sirtuin 1; SREBP1c, sterol regulatory element binding protein-1c; Tbet, T-box transcription factor; TNF-a, tumor necrosis factor a; T h 1, T helper 1; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling; UCLA, University of California, Los Angeles; VHC, vehicle; Z-Asp-cmk, Z-Asp-2,6-dichlorobenzoyloxymethylketone; Z-VD-fmk, Z-Val-Ala-Asp(OMe)-fluoromethylketone.
May 10, 2013 and April 6, 2015. Patients provided informed consent prior to their participation in the study. The demographic data and clinical parameters of recipients and donors are shown in Supporting Table 1 . Routine standard of care and immunosuppressive therapy were administered, as specified by University of California, Los Angeles (UCLA) liver transplant protocols. Study data were collected and managed using REDCap electronic data capture tools hosted at UCLA. All donor organs, procured from donation after brain death with standardized techniques, were perfused with and stored in cold University of Wisconsin solution. Cold ischemia time was defined as the time from the perfusion of the donor with preservation solution to the removal of the liver from cold storage. Recipient blood was collected prior to the transplant and at postoperative day (POD) 1-14. Liver function was evaluated with standard of care tests, including serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Protocol Tru-Cut needle bxs were obtained intraoperatively from the left lobe approximately 2 hours after portal reperfusion (prior to surgical closing of abdomen) and snap-frozen. Early allograft dysfunction (EAD) was defined by the presence of 1 or more of the following: total bilirubin 10 mg/dL (171 lmol/L) or international normalized ratio 1.6 on day 7, and ALT/AST > 2000 IU/ L within the first 7 PODs. 
ANIMALS
Male wild-type mice (C57BL/6; 6-8 weeks of age), purchased from The Jackson Laboratory (Bar Harbor, ME), were housed in the UCLA facility under specific pathogen-free conditions. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised 1985).
REAGENTS
Res, lipopolysaccharide (LPS), and concanavalin A (ConA) were purchased (Sigma Aldrich, St. Louis, MO). Gene-specific small interfering RNA (siRNA) against SIRT1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse macrophage cell line RAW 264.7 (RAW cell) was from the American Type Culture Collection (Manassas, VA).
MOUSE LIVER IRI MODEL
We used an established mouse model of partial hepatic warm IRI. (22, 23) Briefly, animals were anesthetized, injected with heparin (100 U/kg), and an atraumatic clip was used to interrupt artery/portal venous blood supply to the left/middle liver lobes. After 90 minutes of ischemia, the clamp was removed and mice were killed at 6 hours of reperfusion. Res (25 mg/kg) or vehicle (VHC; 15% ethanol) was administrated intraperitoneally (IP) at 1 hour prior to ischemia. Sham-operated mice underwent the same procedure without vascular occlusion.
STATISTICS
Statistical tests were described in each figure/table legend. Survival time was defined from the date of transplantation until the date of death. The cumulative survival was analyzed by Kaplan-Meier method. The cutoff value of human graft SIRT1 expression was determined using receiver operating characteristics (ROC) curve and Youden index on the basis of best accuracy in relation to an outcome (recipient death). P < 0.05 was considered statistically significant. JMP for Windows 8.0 (SAS Institute, Cary, NC) was used for statistical analyses (see Supporting Materials for additional methods).
Results
RES AMELIORATES LIVER IRI
We first examined whether pretreatment with Res (25 mg/kg IP 1 hour) may affect IRI in a murine model of partial liver warm ischemia (90 minutes). The hematoxylin-eosin staining at 6 hours of reperfusion showed well-preserved hepatic architecture (minimal sinusoidal congestion, lobular edema, vacuolization, or necrosis) in the IR1Res group as compared with livers in IR or IR1VHC-treated controls (Fig. 1A) . These data correlated with the Suzuki histological grading of the severity of liver IRI (IR1Res 5 2.5 6 0.8 versus IR 5 4.6 6 1.1 or IR1VHC 5 4.8 6 0.8; n 5 5-6/group; P < 0.05; 
RES ATTENUATES THE HEPATOCELLULAR DEATH AND INFLAMMATORY CELL TRAFFICKING
As shown in Fig. 2A ,B, the immunohistochemistry evaluation revealed a lower frequency of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)1 cells in the IR1Res treatment group as compared with IR or IR1VHC controls (IR1Res 5 15.2 6 3.5 versus IR 5 27.2 6 4.7 or IR1VHC 5 25.1 6 3.6/high-power field [HPF]; n 5 4/ group; P < 0.05). Depressed numbers of neutrophils (lymphocyte antigen 6 complex locus G [Ly6-G]) and macrophages (CD68) were detected in Res-conditioned IR-stressed livers (Ly6-G-IR1Res 5 26.9 6 6.1 versus IR 5 46.7 6 5.2 or IR1VHC 5 42.1 6 6.2/HPF; CD68-IR1Res 5 22.8 6 4.0 versus IR 5 36.9 6 3.8 or IR 1VHC 5 34.9 6 3.6/HPF; n 5 4/group; P < 0.05). Thus, Res treatment ameliorated hepatocellular death and mitigated inflammatory leukocyte homing in IR-stressed livers.
RES UP-REGULATES SIRT1 AND SUPPRESSES PROINFLAMMATORY CYTOKINES IN LIVER IRI
Western blot analysis (Fig. 3A) showed that pretreatment with Res, but not VHC, increased hepatic SIRT1 protein expression, while decreasing leukocyte activation markers (cyclooxygenase 2 [COX-2], inducible nitric oxide synthase [iNOS]). Real-time polymerase chain reaction (RT-PCR) analysis demonstrated that Res, but not VHC, suppressed messenger RNA (mRNA) levels coding for interleukin (IL) 1b, monocyte chemoattractant protein 1 (MCP1), tumor necrosis factor a (TNF-a), and chemokine (C-X-C motif) ligand 10 (CXCL10) with increased level of SIRT1 mRNA (n 5 4/group; P < 0.05; Fig. 3B ). In parallel, Res decreased T-box transcription factor (Tbet) protein (T h 1 master transcription factor) and interferon c (IFNc) mRNA levels (Fig. 3A,B) . Thus, Res treatment suppressed proinflammatory cytokine program and up-regulated SIRT1 expression in IR-stressed livers. Notably, Res increased SIRT1 protein level not only in IRstressed but also nonstressed na€ ıve mouse liver (Fig. 3C ).
SIRT1 INHIBITS MACROPHAGE ACTIVATION IN VITRO
As macrophages play a key role in controlling IRinduced inflammation, we examined LPS-stimulated murine (C57/BL6) bone marrow-derived macrophages (BMDM) cultures. To investigate the function of SIRT1 in macrophage activation, BMDMs were pretreated with siRNA against SIRT1 or Res. As shown in Fig. 4A ,B, SIRT1 silencing triggered enhanced expression of macrophage activation markers (COX-2, iNOS, phospho I kappa B alpha [p-IjBa], phospho signal transducer and activator of transcription 1 [p-Stat1]) and increased levels of mRNA coding for IL1b, MCP1, CXCL10, and C-C motif chemokine ligand 5 (CCL5). These data document that SIRT1 depressed macrophage activation in vitro. Meanwhile, Res supplementation increased SIRT1 levels while exhibiting opposite effects to those after SIRT1 silencing, implying that Res inhibited macrophage activation via SIRT1 signaling. We confirmed regulatory effects of Res supplementation in the RAW cell culture system (Supporting Fig. 1 ). 
RES DEPRESSES LIVER INFILTRATION BY IFNc1 T CELLS
To analyze regulatory effects of Res on IFNc production in vivo, we assessed the frequency of liver-infiltrating 
RES SUPPRESSES T h 1 CYTOKINE PRODUCTION IN VITRO
We employed Con A-activated spleen lymphocyte cultures to analyze how Res may affect T h 1 cytokine program in vitro. As shown in Fig. 6A ,B, addition of Res increased SIRT1 expression and suppressed master transcription regulators (p-Stat1 and Tbet) along with a T h 1-type cytokine program (IFNc and IL2), indicating that Res inhibited T h 1 lymphocyte activation and cytokine production.
SIRT1 POSTREPERFUSION LEVELS IN HUMAN LIVER TRANSPLANTATION
We assessed putative regulatory function of SIRT1 signaling in human liver transplants. Liver bxs were obtained intraoperatively (ca. 2 hours after reperfusion) in 21 patients. Posttransplant relative SIRT1 expression was measured by Western blots. According to the ROC curve and Youden index, the graft SIRT1 cutoff value of 1.53 was determined to be optimal (area under the curve 5 0.79), and based on the cutoff value, liver bxs were divided into "low" versus "high" SIRT1 expression groups (n 5 11 and 10, respectively, Fig.  7A,D) . There was no correlation between SIRT1 levels and donor/recipient background, including cold ischemia time, Model for End-Stage Liver Disease score, age, sex, or body mass index (BMI; Supporting Table 1 ). Postreperfusion high-SIRT1 expression levels correlated with lower ALT/AST levels as compared with low-SIRT1 expression in human OLT, although values did not reach statistical significance (Fig. 7B) . To assess whether local SIRT1 levels may correlate with short-term and longterm outcomes, we analyzed EAD and cumulative posttransplant survival rates. The median follow-up period of 21 patients was 712 days (range, 27-1009 days). None of those individuals underwent secondary liver transplant. Among 21 recipients, 27.3% of the low-SIRT1 bx recipients were diagnosed as EAD, whereas none of the high-SIRT1 bx recipients were within the criterion (P 5 0.12). Noteworthy, cumulative OLT survival with high-SIRT1 bx levels was significantly (P 5 0.04) longer as compared with the low-SIRT1 bx recipient group (Fig. 7C) . Moreover, high-SIRT1 bx demonstrated lower levels of COX-2 and Tbet transcripts (Western blot, Fig. 7D ,E) and proinflammatory cytokines (IL1b, MCP1, TNF-a, CXCL10, and IFNc; RT-PCR, Fig. 7F ). Hence, postreperfusion SIRT1 expression levels in human OLT bx correlated with inflammatory response, liver function, and clinical outcomes.
Discussion
The present study is the first to link postreperfusion SIRT1 expression in human liver transplants with clinical outcomes, including hepatocellular function, proinflammatory cytokine pattern, and patients' survival. By integrating liver transplant clinical data with results from murine liver IRI and in vitro cell culture systems, our findings provide a rationale for further investigating SIRT1 activation in liver transplantation. Indeed, high-SIRT1 postreperfusion levels correlated with depressed proinflammatory response (COX-2/IL1b/TNF-a/ CXCL10 and Tbet/IFNc), preservation of liver function (ALT/AST), and improved patient survival.
Because inflammation is a key feature in the mechanism of liver IRI, (1, 3) the current study focused on the anti-inflammatory role of SIRT1. However, SIRT1 is also known as an antiapoptotic mediator, consistent with a recent report by Yan et al. where SIRT1 silencing increased susceptibility of HepG2 cells to hypoxia/reoxygeneration-induced apoptosis. (24) In our study, treatment of mice with Res or increased SIRT1 expression in human liver grafts correlated with diminished hepatocellular damage, evidenced by serum enzyme levels (Figs. 1C and 7B, respectively), and depressed frequency of TUNEL1 cells in IR-stressed livers ( Fig. 2A,B) . Thus, SIRT1-mediated hepatoprotection results not only from anti-inflammatory effects but also from its direct antiapoptotic function. Cui et al. reported that hepatocyte-specific SIRT1 knockout mice exhibited enhanced nuclear factor kappa B (NF-jB) activity and resistance to apoptosis in an endotoxemic liver injury model. (25) As hepatocyte SIRT1 function against apoptosis may be disease-and/or microenvironmentdependent, future studies with cell-specific SIRT1 mutant mice are warranted. Despite these shortcomings, however, our study presents evidence that global SIRT1 activation was accompanied by reduced liver IRI.
SIRT1 is often referred to as a "longevity gene." Endogenous SIRT1 in human vascular smooth muscle cells is lost with age, (26) whereas SIRT1 expression in mouse livers declined with age at both transcriptional and translational levels. (27) Meanwhile, SIRT1 also relates functionally to human metabolic disorders. Indeed, Nascimento et al. reported that SIRT1 mRNA levels were lower in adipose tissue of obese patients compared with normal-weight controls. (28) In line with these data, we had expected certain correlations between high-SIRT1 graft and younger/lower-BMI donors, though we failed to find significant associations. This may be due to the limited number of patients in our study (n 5 21). Although others have identified a single-nucleotide polymorphism that may change SIRT1 protein expression and anti-oxidant function, (29) future trials on putative factors influencing human SIRT1 responses are warranted.
To induce SIRT1, we used Res, a natural nonflavonoid polyphenol, identified originally as a small molecule SIRT1 activator with antioxidant, cardioprotective, and anticancer properties. (16) Being aware of putative SIRT1-independent Res off-target effects, (17) we applied the siRNA silencing approach to confirm that our findings in BMDM cultures were indeed SIRT1 dependent. We focused on SIRT1 signaling in BMDM because of the following:
1. Circulating monocytes are instrumental in the mechanism of liver IRI. (1, 30) 2. Adoptive transfer of BMDM recreated hepatocellular damage in otherwise IRI-resistant CD11b-DTR mice. (30) 3. Circulating monocytes generate self-renewing Kupffer cells, the resident macrophages in the liver. (31) Consistent with the prominent role of necrosis rather than apoptosis in the mechanism of IR-hepatocellular death, (32) pan caspase inhibitors Z-Asp-2,6-dichlorobenzoyloxymethylketone (Z-Asp-cmk) (32) or Z-ValAla-Asp(OMe)-fluoromethylketone (Z-VD-fmk) (33) failed to protect livers against IRI. However, necrosis and apoptosis are interdependent phenomena resulting from activation of shared signaling pathways (34) and apoptosis precedes necrosis in the pathogenesis of liver IRI. (32, 33) Although some pan caspase inhibitors paradoxically increased necrosis, (35) necroptosis, (36) or autophagic cell death, (37) it is noteworthy that a novel caspase inhibitor IDN-6556 reduced liver IRI in a murine model (38) and offered local therapeutic protection in a phase 2 trial in human liver transplantation. (39) We reported that hepatoprotection after treatment with 7-Cl-O-Nec-1 necrosis inhibitor (Nec-1s) was lost when Kupffer cells were deleted by clodronate, indicating that Nec-1s failed to mitigate liver cell death in an IR-stressed liver. (40) Thus, consistent with beneficial effects of Res, accompanied by decreased cleaved caspase 3 (Fig. 3A) , targeting hepatocellular apoptosis is required to ameliorate liver IRI.
SIRT1, a member of the class III histone deacetylase (HDAC) family, may deacetylate not only histone but also nonhistone proteins. Previous studies focused on deacetylation function to nonhistone target proteins, including NF-jB, (25) PGC-1a, (41) and sterol regulatory element binding protein-1c (SREBP1c). (42) Although cytoprotective and organ protective effect of HDAC inhibitors were documented in some animal models, (43, 44) little is known of how histone deacetylation may affect an IR-stressed liver. Indeed, butyrate (class I/II HDAC inhibitor) was shown to alleviate rat liver IRI, (45) whereas valproic acid (pan-HDAC inhibitor) failed to protect rat liver against IR stress. (46) Further evaluation of HDAC inhibitors, especially those readily available in daily medical practice, is warranted.
We acknowledge the limitations of our study. First, we are aware Res may produce SIRT1-independent effects, eg, antioxidative function in cultured renal proximal tubular cells (47) ; autophagy by directly inhibiting mammalian target of rapamycin in human cervical cancer cell line (HeLa cells) (48) ; or inhibition of insulin-induced mitogen-activated protein kinase/Akt phosphorylations in human embryonic kidney 293 cells. (49) Hence, hepatoprotection after adjunctive Res might result from off-target effects rather than upregulation of SIRT1 signaling per se. Second, although our murine and human transplant bx data consistently demonstrated correlations between SIRT1 expression and the outcomes, we cannot document the causality, because of the aforementioned off-target effects and IR stress itself decreasing SIRT1 expression in the liver (Fig. 3A) . Future studies in SIRT1 mutant animals are needed to confirm our findings. Third, as timing of postoperative blood collection varied between clinical subjects, the evaluation of pretransplant/posttransplant liver function may be not totally accurate. Fourth, with clinical bx samples from a limited number of patients evaluated retrospectively, significant differences between the high-versus low-SIRT1 expression groups were detected in some parameters only (cumulative survival; Tbet/IL1b OLT expression). Although other differences did not reach statistical significance, low-SIRT1 bx samples tended to associate with "older" recipient age and increased intraoperative "blood loss" (Supporting Table 1 ). As we cannot eliminate the possibility of inferior clinical outcomes influenced by these factors, studies in larger patient cohorts merit further research.
In conclusion, while the experimental arm of our study confirmed the beneficial anti-inflammatory functions of SIRT1 induction in murine IRI, our clinical data are the first to identify SIRT1 as an important regulator of hepatocellular function in human liver transplants under IR stress. By targeting innate (macrophage) and adaptive (T cell) immune activation, SIRT1 manipulation should be considered as a novel therapeutic means to combat inflammation and tissue damage in liver transplantation.
